Open Access

Gemcitabine resistance in triple‑negative breast cancer cells can be reverted by Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol

  • Authors:
    • Yan Zhao
    • Haiyang Jiang
    • Ming Gu
    • Cong Zu
    • Xinyu Zheng
  • View Affiliations

  • Published online on: September 15, 2020     https://doi.org/10.3892/ol.2020.12109
  • Article Number: 247
  • Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The development of drug resistance to chemotherapeutic agents has consistently presented a challenge in terms of the treatment of patients with triple‑negative breast cancer (TNBC). In the present study, gemcitabine (dFdC)‑resistant TNBC cells were established, and the effects of lentivirus‑deoxyribonucleoside kinase (dNK) and a mutated form of dNK (lentivirus‑dNKmut) on reversing the acquired drug resistance in dFdC‑resistant TNBC cells were explored. Quantitative PCR and western blotting experiment results suggested that Drosophila melanogaster (Dm)‑dNK was stably expressed in the lentivirus‑infected MDA‑MB‑231 and MDA-MB-231R cells in the nucleus or cytosol, and autoradiography experiments revealed similar levels of enzymatic activity in the cells expressing dNK or dNKmut. In vitro cytotoxicity assay revealed that the IC50 values of dFdC were decreased 30~50‑fold in the dFdC‑resistant MDA‑MB‑231 cells following lentiviral transfection with dNK or dNKmut, and this effect was associated with a significantly increased rate of apoptosis compared with the cells transfected with the negative control lentivirus. In conclusion, Dm‑dNK in the nucleus or cytosol may be a potential candidate for reversing acquired dFdC resistance in TNBC cells, which may form the basis of novel strategies for the treatment of patients with drug‑resistant TNBC.
View Figures
View References

Related Articles

Journal Cover

November-2020
Volume 20 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhao Y, Jiang H, Gu M, Zu C and Zheng X: Gemcitabine resistance in triple‑negative breast cancer cells can be reverted by <em>Drosophila melanogaster</em> deoxyribonucleoside kinase in the nucleus or cytosol. Oncol Lett 20: 247, 2020.
APA
Zhao, Y., Jiang, H., Gu, M., Zu, C., & Zheng, X. (2020). Gemcitabine resistance in triple‑negative breast cancer cells can be reverted by <em>Drosophila melanogaster</em> deoxyribonucleoside kinase in the nucleus or cytosol. Oncology Letters, 20, 247. https://doi.org/10.3892/ol.2020.12109
MLA
Zhao, Y., Jiang, H., Gu, M., Zu, C., Zheng, X."Gemcitabine resistance in triple‑negative breast cancer cells can be reverted by <em>Drosophila melanogaster</em> deoxyribonucleoside kinase in the nucleus or cytosol". Oncology Letters 20.5 (2020): 247.
Chicago
Zhao, Y., Jiang, H., Gu, M., Zu, C., Zheng, X."Gemcitabine resistance in triple‑negative breast cancer cells can be reverted by <em>Drosophila melanogaster</em> deoxyribonucleoside kinase in the nucleus or cytosol". Oncology Letters 20, no. 5 (2020): 247. https://doi.org/10.3892/ol.2020.12109